Get the Stockscreener App
26.69
2.30%
0.60
After Hours:
26.69
Edgewise Therapeutics Inc stock is traded at $26.69, with a volume of 749.84K.
It is up +2.30% in the last 24 hours and up +42.35% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
See More
Previous Close:
$26.09
Open:
$26.09
24h Volume:
749.84K
Relative Volume:
0.64
Market Cap:
$2.47B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-19.92
EPS:
-1.34
Net Cash Flow:
$-104.72M
1W Performance:
+0.76%
1M Performance:
+42.35%
6M Performance:
+46.33%
1Y Performance:
+365.79%
1-Day Range:
$25.86
$26.95
1-Week Range:
$24.90
$27.09
52-Week Range:
$5.12
$30.00
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Balance Sheet Breakdown: Edgewise Therapeutics Inc (EWTX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
How did Edgewise Therapeutics Inc (EWTX) fare last session? - US Post News
The Potential Rise in the Price of Edgewise Therapeutics Inc (EWTX) following insiders activity - Knox Daily
Perceptive Advisors LLC Sells 463,229 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Frazier Life Sciences Management L.P. Buys 427,500 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Duchenne Muscular Dystrophy Treatment Drugs, Clinical Trials, Pipeline Insights and Companies 2024 - The Globe and Mail
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge - Benzinga
Analyst Think There's Still Time to Get in on Edgewise, Up 332% - MSN
Edgewise Therapeutics Inc (EWTX)’s Market Momentum: Closing Strong at 25.92, Down -2.15 - The Dwinnex
Analysts Think There's Still Time to Get in on Edgewise, Up 332% - MarketBeat
Bristol-Myers Squibb Company (BMY-N) QuotePress Release - The Globe and Mail
This trade activity should not be overlooked: Edgewise Therapeutics Inc (EWTX) - SETE News
Edgewise Therapeutics general counsel sells over $1.9m in company stock By Investing.com - Investing.com South Africa
Insider Selling: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) General Counsel Sells 50,000 Shares of Stock - Defense World
Alan J. Russell Sells 75,000 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) General Counsel Sells $578,074.86 in Stock - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) CMO Joanne M. Donovan Sells 7,162 Shares - Defense World
R Michael Carruthers Sells 125,092 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock - Defense World
Edgewise Therapeutics CMO sells $202k in company stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CFO sells over $3.5 million in company stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CFO sells over $3.5 million in company stock By Investing.com - Investing.com Canada
Edgewise Therapeutics executive sells over $1.2m in stock By Investing.com - Investing.com Canada
Edgewise Therapeutics CSO sells over $2 million in company stock By Investing.com - Investing.com Canada
Edgewise Therapeutics executive sells over $1.2m in stock - Investing.com
Edgewise Therapeutics executive sells over $1.2m in stock - Investing.com India
Edgewise Therapeutics executive sells over $1.2m in stock By Investing.com - Investing.com Australia
Edgewise Therapeutics CMO sells $202k in company stock - Investing.com
Edgewise Therapeutics CFO sells over $3.5 million in company stock - Investing.com
Edgewise Therapeutics CSO sells over $2 million in company stock By Investing.com - Investing.com UK
Edgewise Therapeutics CMO sells $202k in company stock By Investing.com - Investing.com UK
Edgewise Therapeutics - The Pharma Letter
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.9% - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.9% - Defense World
Edgewise Therapeutics Inc (EWTX) produces promising results - US Post News
46,234 Shares in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Acquired by Federated Hermes Inc. - Defense World
Federated Hermes Inc. Takes Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? - Benzinga
Why Edgewise Therapeutics Stock Is Up 50% on Thursday - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Hits New 1-Year High After Analyst Upgrade - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Bought by American Century Companies Inc. - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Hits New 52-Week High Following Analyst Upgrade - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Bought by American Century Companies Inc. - MarketBeat
Rhumbline Advisers Purchases 14,041 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up to $18.08 - Defense World
Edgewise Therapeutics Inc [EWTX] stock Initiated by Piper Sandler analyst, price target now $48 - The DBT News
Edgewise’s Early Cardiomyopathy Data Builds Case For A Blockbuster - Scrip
Edgewise shares jump after positive heart drug data - The Pharma Letter
Edgewise Therapeutics Shares Soar 50% on Promising Early Data for HCM Drug EDG-7500 - Zenopa
Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $33.00 at Truist Financial - Defense World
Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials - Clinical Trials Arena
Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials - Yahoo Finance
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):